Bayer Hopeful Of Sweet Success With KaNDy Buy
Gets Hold Of Late-Stage Non-Hormonal Menopause Drug
Executive Summary
Bayer is paying $425m upfront to acquire KaNDy Therapeutics, whose CEO tells Scrip that the German group was always the preferred partner due to its long-standing commitment to women’s health.
You may also be interested in...
Bayer’s Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs
The company is struggling to grow revenue, and the biggest of its four key late-stage assets had a setback, but novel technologies are fueling an R&D strategy shift towards high potential programs.
Menopause Drug A Priority For Astellas
The Japanese group has used a priority review voucher for fezolinetant to move further ahead of Bayer’s elinzanetant as it seeks regulatory approval to bring a non-hormonal therapy for menopausal symptoms such as hot flashes and night sweats to market.
Astellas’s Long-Term Safety Data Could Boost Fezolinetant’s Approval Chances
With a pair of successful Phase III pivotal studies in hand, the Japanese pharma reports that its nonhormonal hot flash/night sweats candidate demonstrated safety and tolerability over 52 weeks.